|Awarded On||February 21, 2019|
|Title||Pharmacological Targeting of the IRE1/XBP1 Pathway for Triple-Negative Breast Cancer Therapy|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Albert Koong|
*Pending contract negotiation
Amongst women in the United States, breast cancer is the most common cancer and the second leading cause of cancer-related deaths. Worldwide, it is the leading cause of cancer-related deaths among women. Triple-negative breast cancers (TNBCs), a well-defined subtype of breast cancer that lacks specific hormonal and membrane receptors, represent a particularly aggressive form of breast cancer. TNBCs, accounting for 10-24% of all breast cancers, grow rapidly and develop metastases affecting vital organs, resulting in poor overall survival. More effective therapeutic agents for TNBCs are critically needed. Recently, we and others identified that a pro-survival protein, XBP1, promotes the growth...